<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32192534</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-994X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genome medicine</Title>
          <ISOAbbreviation>Genome Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tracking cancer progression: from circulating tumor cells to metastasis.</ArticleTitle>
        <Pagination>
          <StartPage>31</StartPage>
          <MedlinePgn>31</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">31</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13073-020-00728-3</ELocationID>
        <Abstract>
          <AbstractText>The analysis of circulating tumor cells (CTCs) is an outstanding tool to provide insights into the biology of metastatic cancers, to monitor disease progression and with potential for use in liquid biopsy-based personalized cancer treatment. These goals are ambitious, yet recent studies are already allowing a sharper understanding of the strengths, challenges, and opportunities provided by liquid biopsy approaches. For instance, through single-cell-resolution genomics and transcriptomics, it is becoming increasingly clear that CTCs are heterogeneous at multiple levels and that only a fraction of them is capable of initiating metastasis. It also appears that CTCs adopt multiple ways to enhance their metastatic potential, including homotypic clustering and heterotypic interactions with immune and stromal cells. On the clinical side, both CTC enumeration and molecular analysis may provide new means to monitor cancer progression and to take individualized treatment decisions, but their use for early cancer detection appears to be challenging compared to that of other tumor derivatives such as circulating tumor DNA. In this review, we summarize current data on CTC biology and CTC-based clinical applications that are likely to impact our understanding of the metastatic process and to influence the clinical management of patients with metastatic cancer, including new prospects that may favor the implementation of precision medicine.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Castro-Giner</LastName>
            <ForeName>Francesc</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Swiss Institute of Bioinformatics, 1015, Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aceto</LastName>
            <ForeName>Nicola</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, 4058, Basel, Switzerland. Nicola.Aceto@unibas.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Genome Med</MedlineTA>
        <NlmUniqueID>101475844</NlmUniqueID>
        <ISSNLinking>1756-994X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>NA is listed as an inventor in patent applications related to CTCs, and he is a paid consultant for companies that have an interest in liquid biopsy. FCG declares that he has no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32192534</ArticleId>
        <ArticleId IdType="pmc">PMC7082968</ArticleId>
        <ArticleId IdType="doi">10.1186/s13073-020-00728-3</ArticleId>
        <ArticleId IdType="pii">10.1186/s13073-020-00728-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Aceto N, Toner M, Maheswaran S, Haber DA. En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer. 2015;1:44–52. doi: 10.1016/j.trecan.2015.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2015.07.006</ArticleId>
            <ArticleId IdType="pubmed">28741562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–118. doi: 10.1373/clinchem.2012.194258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2012.194258</ArticleId>
            <ArticleId IdType="pubmed">23014601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623–631. doi: 10.1038/nrc3820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3820</ArticleId>
            <ArticleId IdType="pubmed">25154812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192:373–382. doi: 10.1083/jcb.201010021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201010021</ArticleId>
            <ArticleId IdType="pmc">PMC3101098</ArticleId>
            <ArticleId IdType="pubmed">21300848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al.  Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13:920–928. doi: 10.1158/1078-0432.CCR-06-1695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-1695</ArticleId>
            <ArticleId IdType="pubmed">17289886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agerbæk MØ, Bang-Christensen SR, Yang MH, Clausen TM, Pereira MA, Sharma S, et al.  The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat Commun. 2018;9:3279. doi: 10.1038/s41467-018-05793-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-05793-2</ArticleId>
            <ArticleId IdType="pmc">PMC6095877</ArticleId>
            <ArticleId IdType="pubmed">30115931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim TH, Wang Y, Oliver CR, Thamm DH, Cooling L, Paoletti C, et al.  A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. Nat Commun. 2019;10:1478. doi: 10.1038/s41467-019-09439-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-09439-9</ArticleId>
            <ArticleId IdType="pmc">PMC6443676</ArticleId>
            <ArticleId IdType="pubmed">30932020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch System in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421. doi: 10.1155/2010/617421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2010/617421</ArticleId>
            <ArticleId IdType="pmc">PMC2793426</ArticleId>
            <ArticleId IdType="pubmed">20016752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H, Kim J, Song H, Sohn KY, Jeon M, Han KH. Microfluidic technologies for circulating tumor cell isolation. Analyst. 2018;143:2936–2970. doi: 10.1039/C7AN01979C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C7AN01979C</ArticleId>
            <ArticleId IdType="pubmed">29796523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409–424. doi: 10.1038/s41571-019-0187-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-019-0187-3</ArticleId>
            <ArticleId IdType="pubmed">30796368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes Dev. 2017;31:1827–1840. doi: 10.1101/gad.305805.117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.305805.117</ArticleId>
            <ArticleId IdType="pmc">PMC5695084</ArticleId>
            <ArticleId IdType="pubmed">29051388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, et al.  Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32:479–484. doi: 10.1038/nbt.2892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2892</ArticleId>
            <ArticleId IdType="pmc">PMC4034575</ArticleId>
            <ArticleId IdType="pubmed">24752078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20:897–903. doi: 10.1038/nm.3600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3600</ArticleId>
            <ArticleId IdType="pubmed">24880617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al.  Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216–220. doi: 10.1126/science.1253533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1253533</ArticleId>
            <ArticleId IdType="pmc">PMC4358808</ArticleId>
            <ArticleId IdType="pubmed">25013076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, et al.  Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res. 2015;75:892–901. doi: 10.1158/0008-5472.CAN-14-2613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-2613</ArticleId>
            <ArticleId IdType="pubmed">25592149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tellez-Gabriel M, Cochonneau D, Cadé M, Jubellin C, Heymann MF, Heymann D. Circulating tumor cell-derived pre-clinical models for personalized medicine. Cancers (Basel). 2018;11. doi:10.3390/cancers11010019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6356998</ArticleId>
            <ArticleId IdType="pubmed">30586936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murlidhar V, Reddy RM, Fouladdel S, Zhao L, Ishikawa MK, Grabauskiene S, et al.  Poor prognosis indicated by venous circulating tumor cell clusters in early-stage lung cancers. Cancer Res. 2017;77:5194–5206. doi: 10.1158/0008-5472.CAN-16-2072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2072</ArticleId>
            <ArticleId IdType="pmc">PMC5600850</ArticleId>
            <ArticleId IdType="pubmed">28716896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Navin NE. Advances and applications of single-cell sequencing technologies. Mol Cell. 2015;58:598–609. doi: 10.1016/j.molcel.2015.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2015.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC4441954</ArticleId>
            <ArticleId IdType="pubmed">26000845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abouleila Y, Onidani K, Ali A, Shoji H, Kawai T, Lim CT, et al.  Live single cell mass spectrometry reveals cancer-specific metabolic profiles of circulating tumor cells. Cancer Sci. 2019;110:697–706. doi: 10.1111/cas.13915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13915</ArticleId>
            <ArticleId IdType="pmc">PMC6361580</ArticleId>
            <ArticleId IdType="pubmed">30549153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng YH, Chen YC, Lin E, Brien R, Jung S, Chen YT, et al.  Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat Commun. 2019;10:2163. doi: 10.1038/s41467-019-10122-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-10122-2</ArticleId>
            <ArticleId IdType="pmc">PMC6520360</ArticleId>
            <ArticleId IdType="pubmed">31092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al.  Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–1122. doi: 10.1016/j.cell.2014.07.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.07.013</ArticleId>
            <ArticleId IdType="pmc">PMC4149753</ArticleId>
            <ArticleId IdType="pubmed">25171411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macaulay IC, Ponting CP, Voet T. Single-cell multiomics: multiple measurements from single cells. Trends Genet. 2017;33:155–168. doi: 10.1016/j.tig.2016.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tig.2016.12.003</ArticleId>
            <ArticleId IdType="pmc">PMC5303816</ArticleId>
            <ArticleId IdType="pubmed">28089370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angermueller C, Clark SJ, Lee HJ, Macaulay IC, Teng MJ, Hu TX, et al.  Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity. Nat Methods. 2016;13:229–232. doi: 10.1038/nmeth.3728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.3728</ArticleId>
            <ArticleId IdType="pmc">PMC4770512</ArticleId>
            <ArticleId IdType="pubmed">26752769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macaulay IC, Haerty W, Kumar P, Li YI, Hu TX, Teng MJ, et al.  G&amp;T-seq: parallel sequencing of single-cell genomes and transcriptomes. Nat Methods. 2015;12:519–522. doi: 10.1038/nmeth.3370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.3370</ArticleId>
            <ArticleId IdType="pubmed">25915121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey SS, Kester L, Spanjaard B, Bienko M, van Oudenaarden A. Integrated genome and transcriptome sequencing of the same cell. Nat Biotechnol. 2015;33:285–289. doi: 10.1038/nbt.3129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.3129</ArticleId>
            <ArticleId IdType="pmc">PMC4374170</ArticleId>
            <ArticleId IdType="pubmed">25599178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current state of the science. Nat Rev Genet. 2016;17:175–188. doi: 10.1038/nrg.2015.16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg.2015.16</ArticleId>
            <ArticleId IdType="pubmed">26806412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, et al.  Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res. 2009;15:2091–2097. doi: 10.1158/1078-0432.CCR-08-2036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-2036</ArticleId>
            <ArticleId IdType="pmc">PMC2875199</ArticleId>
            <ArticleId IdType="pubmed">19276271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onozato ML, Yapp C, Richardson D, Sundaresan T, Chahal V, Lee J, et al.  Highly multiplexed fluorescence in situ hybridization for in situ genomics. J Mol Diagn. 2019;21:390–407. doi: 10.1016/j.jmoldx.2019.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmoldx.2019.01.010</ArticleId>
            <ArticleId IdType="pmc">PMC6504678</ArticleId>
            <ArticleId IdType="pubmed">30862547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, et al.  Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016;7:26107–26119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5041968</ArticleId>
            <ArticleId IdType="pubmed">27034166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, et al.  Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A. 2013;110:21083–21088. doi: 10.1073/pnas.1320659110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1320659110</ArticleId>
            <ArticleId IdType="pmc">PMC3876226</ArticleId>
            <ArticleId IdType="pubmed">24324171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, et al.  Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2017;23:114–119. doi: 10.1038/nm.4239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4239</ArticleId>
            <ArticleId IdType="pubmed">27869802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73:2965–2975. doi: 10.1158/0008-5472.CAN-12-4140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-12-4140</ArticleId>
            <ArticleId IdType="pubmed">23471846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorges TM, Kuske A, Röck K, Mauermann O, Müller V, Peine S, et al.  Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clin Chem. 2016;62:1504–1515. doi: 10.1373/clinchem.2016.260299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2016.260299</ArticleId>
            <ArticleId IdType="pubmed">27630154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasch C, Plummer PN, Jovanovic L, McInnes LM, Wescott D, Saunders CM, et al.  Heterogeneity of miR-10b expression in circulating tumor cells. Sci Rep. 2015;5:15980. doi: 10.1038/srep15980.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep15980</ArticleId>
            <ArticleId IdType="pmc">PMC4629160</ArticleId>
            <ArticleId IdType="pubmed">26522916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al.  Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–584. doi: 10.1126/science.1228522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1228522</ArticleId>
            <ArticleId IdType="pmc">PMC3760262</ArticleId>
            <ArticleId IdType="pubmed">23372014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortega FG, Lorente JA, Garcia Puche JL, Ruiz MP, Sanchez-Martin RM, de Miguel-Pérez D, et al.  miRNA in situ hybridization in circulating tumor cells—MishCTC. Sci Rep. 2015;5:9207. doi: 10.1038/srep09207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep09207</ArticleId>
            <ArticleId IdType="pmc">PMC4361864</ArticleId>
            <ArticleId IdType="pubmed">25777797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, et al.  Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014;8:1905–1918. doi: 10.1016/j.celrep.2014.08.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.08.029</ArticleId>
            <ArticleId IdType="pmc">PMC4230325</ArticleId>
            <ArticleId IdType="pubmed">25242334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349:1351–1356. doi: 10.1126/science.aab0917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aab0917</ArticleId>
            <ArticleId IdType="pmc">PMC4872391</ArticleId>
            <ArticleId IdType="pubmed">26383955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pixberg CF, Raba K, Müller F, Behrens B, Honisch E, Niederacher D, et al.  Analysis of DNA methylation in single circulating tumor cells. Oncogene. 2017;36:3223–3231. doi: 10.1038/onc.2016.480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2016.480</ArticleId>
            <ArticleId IdType="pubmed">28068321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, et al.  Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176:98–112. doi: 10.1016/j.cell.2018.11.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.11.046</ArticleId>
            <ArticleId IdType="pmc">PMC6363966</ArticleId>
            <ArticleId IdType="pubmed">30633912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klotz R, Thomas A, Teng T, Han SM, Iriondo O, Li L, et al.  Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers. Cancer Discov. 2020;10:86–103. doi: 10.1158/2159-8290.CD-19-0384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0384</ArticleId>
            <ArticleId IdType="pmc">PMC6954305</ArticleId>
            <ArticleId IdType="pubmed">31601552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, et al.  Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res. 2015;21:2487–2498. doi: 10.1158/1078-0432.CCR-14-1913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1913</ArticleId>
            <ArticleId IdType="pmc">PMC5516625</ArticleId>
            <ArticleId IdType="pubmed">25381338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinkala E, Sollier-Christen E, Renier C, Rosàs-Canyelles E, Che J, Heirich K, et al.  Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nat Commun. 2017;8:14622. doi: 10.1038/ncomms14622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14622</ArticleId>
            <ArticleId IdType="pmc">PMC5376644</ArticleId>
            <ArticleId IdType="pubmed">28332571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerdtsson E, Pore M, Thiele JA, Gerdtsson AS, Malihi PD, Nevarez R, et al. Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Converg Sci Phys Oncol. 2018;4. 10.1088/2057-1739/aaa013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6430142</ArticleId>
            <ArticleId IdType="pubmed">30906572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, et al.  HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016;537:102–106. doi: 10.1038/nature19328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature19328</ArticleId>
            <ArticleId IdType="pmc">PMC5161614</ArticleId>
            <ArticleId IdType="pubmed">27556950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al.  Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553–557. doi: 10.1038/s41586-019-0915-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-0915-y</ArticleId>
            <ArticleId IdType="pubmed">30728496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Rydén L. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16:433. doi: 10.1186/s12885-016-2406-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-016-2406-y</ArticleId>
            <ArticleId IdType="pmc">PMC4938919</ArticleId>
            <ArticleId IdType="pubmed">27390845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, et al.  Perspective on circulating tumor cell clusters: why it takes a village to metastasize. Cancer Res. 2018;78:845–852. doi: 10.1158/0008-5472.CAN-17-2748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-2748</ArticleId>
            <ArticleId IdType="pubmed">29437766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, Zhao L, Zhou P, Ma H, Huang F, Jin M, et al.  Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. Cancer Cell Int. 2017;17:6. doi: 10.1186/s12935-016-0373-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-016-0373-7</ArticleId>
            <ArticleId IdType="pmc">PMC5217234</ArticleId>
            <ArticleId IdType="pubmed">28070168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, et al.  Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res Treat. 2017;161:83–94. doi: 10.1007/s10549-016-4026-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-016-4026-2</ArticleId>
            <ArticleId IdType="pubmed">27771841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649–5669. doi: 10.1158/0008-5472.CAN-10-1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-1040</ArticleId>
            <ArticleId IdType="pmc">PMC4037932</ArticleId>
            <ArticleId IdType="pubmed">20610625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeidman I, Buss JM. Transpulmonary passage of tumor cell emboli. Cancer Res. 1952;12:731–733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12988202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976;36:889–894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1253177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler IJ. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer. 1973;9:223–227. doi: 10.1016/S0014-2964(73)80022-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-2964(73)80022-2</ArticleId>
            <ArticleId IdType="pubmed">4787857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–458. doi: 10.1038/nrc1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1098</ArticleId>
            <ArticleId IdType="pubmed">12778135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labuschagne CF, Cheung EC, Blagih J, Domart MC, Vousden KH. Cell clustering promotes a metabolic switch that supports metastatic colonization. Cell Metab. 2019;30:720–734. doi: 10.1016/j.cmet.2019.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2019.07.014</ArticleId>
            <ArticleId IdType="pmc">PMC6863392</ArticleId>
            <ArticleId IdType="pubmed">31447323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Taftaf R, Kawaguchi M, Chang YF, Chen W, Entenberg D, et al.  Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discov. 2019;9:96–113. doi: 10.1158/2159-8290.CD-18-0065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-18-0065</ArticleId>
            <ArticleId IdType="pmc">PMC6328322</ArticleId>
            <ArticleId IdType="pubmed">30361447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawaguchi M, et al. Extracellular domains I-II of cell-surface glycoprotein CD44 mediate its trans-homophilic dimerization and tumor cluster aggregation. J Biol Chem. 2020. 10.1074/jbc.RA119.010252jbc.RA119.010252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7049959</ArticleId>
            <ArticleId IdType="pubmed">31969394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, et al.  Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A. 2016;113:E854–E863. doi: 10.1073/pnas.1508541113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1508541113</ArticleId>
            <ArticleId IdType="pmc">PMC4763783</ArticleId>
            <ArticleId IdType="pubmed">26831077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li CF, Chen JY, Ho YH, Hsu WH, Wu LC, Lan HY, et al.  Snail-induced claudin-11 prompts collective migration for tumour progression. Nat Cell Biol. 2019;21:251–262. doi: 10.1038/s41556-018-0268-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-018-0268-z</ArticleId>
            <ArticleId IdType="pubmed">30664792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padmanaban V, Krol I, Suhail Y, Szczerba BM, Aceto N, Bader JS, Ewald AJ. E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 2019;573:439–444. doi: 10.1038/s41586-019-1526-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1526-3</ArticleId>
            <ArticleId IdType="pmc">PMC7365572</ArticleId>
            <ArticleId IdType="pubmed">31485072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang PY, Brenot A, King AC, Longmore GD, George SC. Randomly distributed K14(+) breast tumor cells polarize to the leading edge and guide collective migration in response to chemical and mechanical environmental cues. Cancer Res. 2019;79:1899–1912. doi: 10.1158/0008-5472.CAN-18-2828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-2828</ArticleId>
            <ArticleId IdType="pmc">PMC6467777</ArticleId>
            <ArticleId IdType="pubmed">30862718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al.  The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520:353–357. doi: 10.1038/nature14347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14347</ArticleId>
            <ArticleId IdType="pmc">PMC4413032</ArticleId>
            <ArticleId IdType="pubmed">25830880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddipati R, Stanger BZ. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 2015;5:1086–1097. doi: 10.1158/2159-8290.CD-15-0120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-0120</ArticleId>
            <ArticleId IdType="pmc">PMC4657730</ArticleId>
            <ArticleId IdType="pubmed">26209539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brouwer A, De Laere B, Peeters D, Peeters M, Salgado R, Dirix L, Van Laere S. Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget. 2016;7:48625–48643. doi: 10.18632/oncotarget.8015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8015</ArticleId>
            <ArticleId IdType="pmc">PMC5217044</ArticleId>
            <ArticleId IdType="pubmed">26980749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kong SL, Liu X, Suhaimi NM, Koh KJH, Hu M, Lee DYS, et al.  Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care. Oncotarget. 2017;8:68026–68037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5620233</ArticleId>
            <ArticleId IdType="pubmed">28978093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today. 2019;24:763–772. doi: 10.1016/j.drudis.2018.11.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drudis.2018.11.017</ArticleId>
            <ArticleId IdType="pubmed">30496853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, et al.  Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24:1867–1876. doi: 10.1038/s41591-018-0269-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0269-2</ArticleId>
            <ArticleId IdType="pubmed">30523328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, et al.  The mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep. 2017;19:218–224. doi: 10.1016/j.celrep.2017.03.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2017.03.025</ArticleId>
            <ArticleId IdType="pmc">PMC5439509</ArticleId>
            <ArticleId IdType="pubmed">28380360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riebensahm C, Joosse SA, Mohme M, Hanssen A, Matschke J, Goy Y, et al.  Clonality of circulating tumor cells in breast cancer brain metastasis patients. Breast Cancer Res. 2019;21:101. doi: 10.1186/s13058-019-1184-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-019-1184-2</ArticleId>
            <ArticleId IdType="pmc">PMC6720990</ArticleId>
            <ArticleId IdType="pubmed">31481116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, et al.  Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res. 2018;78:1110–1122. doi: 10.1158/0008-5472.CAN-17-2686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-2686</ArticleId>
            <ArticleId IdType="pmc">PMC5815882</ArticleId>
            <ArticleId IdType="pubmed">29233927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, et al.  Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun. 2017;8:196. doi: 10.1038/s41467-017-00196-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-00196-1</ArticleId>
            <ArticleId IdType="pmc">PMC5543046</ArticleId>
            <ArticleId IdType="pubmed">28775303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto DT, Ting DT, Toner M, Maheswaran S, Haber DA. Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity. Cold Spring Harb Symp Quant Biol. 2016;81:269–274. doi: 10.1101/sqb.2016.81.031120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/sqb.2016.81.031120</ArticleId>
            <ArticleId IdType="pmc">PMC5501288</ArticleId>
            <ArticleId IdType="pubmed">28389596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, et al.  Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res. 2016;22:1103–1110. doi: 10.1158/1078-0432.CCR-15-1031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1031</ArticleId>
            <ArticleId IdType="pmc">PMC4775471</ArticleId>
            <ArticleId IdType="pubmed">26446944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasch C, Oldopp T, Mauermann O, Gorges TM, Andreas A, Coith C, et al.  Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer. Mol Oncol. 2016;10:1330–1343. doi: 10.1016/j.molonc.2016.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2016.07.005</ArticleId>
            <ArticleId IdType="pmc">PMC5423206</ArticleId>
            <ArticleId IdType="pubmed">27491860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun YF, Guo W, Xu Y, Shi YH, Gong ZJ, Ji Y, et al.  Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma. Clin Cancer Res. 2018;24:547–559. doi: 10.1158/1078-0432.CCR-17-1063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-1063</ArticleId>
            <ArticleId IdType="pubmed">29070526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim SB, Yeo T, Lee WD, Bhagat AAS, Tan SJ, Tan DSW, et al.  Addressing cellular heterogeneity in tumor and circulation for refined prognostication. Proc Natl Acad Sci U S A. 2019;116:17957–17962. doi: 10.1073/pnas.1907904116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1907904116</ArticleId>
            <ArticleId IdType="pmc">PMC6731691</ArticleId>
            <ArticleId IdType="pubmed">31416912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merino D, Weber TS, Serrano A, Vaillant F, Liu K, Pal B, et al.  Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nat Commun. 2019;10:766. doi: 10.1038/s41467-019-08595-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-08595-2</ArticleId>
            <ArticleId IdType="pmc">PMC6377663</ArticleId>
            <ArticleId IdType="pubmed">30770823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celià-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016;30:892–908. doi: 10.1101/gad.277681.116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.277681.116</ArticleId>
            <ArticleId IdType="pmc">PMC4840296</ArticleId>
            <ArticleId IdType="pubmed">27083997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–544. doi: 10.1038/nbt.2576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2576</ArticleId>
            <ArticleId IdType="pubmed">23609047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19:1438–1449. doi: 10.1038/nm.3336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3336</ArticleId>
            <ArticleId IdType="pmc">PMC4190672</ArticleId>
            <ArticleId IdType="pubmed">24202396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celià-Terrassa T, Meca-Cortés O, Mateo F, Martínez de Paz A, Rubio N, Arnal-Estapé A, et al.  Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest. 2012;122:1849–1868. doi: 10.1172/JCI59218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI59218</ArticleId>
            <ArticleId IdType="pmc">PMC3366719</ArticleId>
            <ArticleId IdType="pubmed">22505459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527:472–476. doi: 10.1038/nature15748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15748</ArticleId>
            <ArticleId IdType="pmc">PMC4662610</ArticleId>
            <ArticleId IdType="pubmed">26560033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al.  Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–530. doi: 10.1038/nature16064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature16064</ArticleId>
            <ArticleId IdType="pmc">PMC4849281</ArticleId>
            <ArticleId IdType="pubmed">26560028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jolly MK, Mani SA, Levine H. Hybrid epithelial/mesenchymal phenotype(s): the ‘fittest’ for metastasis? Biochim Biophys Acta Rev Cancer. 1870;2018:151–157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29997040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jolly MK, Boareto M, Huang B, Jia D, Lu M, Ben-Jacob E, et al.  Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol. 2015;5:155. doi: 10.3389/fonc.2015.00155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2015.00155</ArticleId>
            <ArticleId IdType="pmc">PMC4507461</ArticleId>
            <ArticleId IdType="pubmed">26258068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al.  Identification of the tumour transition states occurring during EMT. Nature. 2018;556:463–468. doi: 10.1038/s41586-018-0040-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0040-3</ArticleId>
            <ArticleId IdType="pubmed">29670281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grosse-Wilde A, Fouquier d'Hérouël A, McIntosh E, Ertaylan G, Skupin A, Kuestner RE, et al.  Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS One. 2015;10:e0126522. doi: 10.1371/journal.pone.0126522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0126522</ArticleId>
            <ArticleId IdType="pmc">PMC4447403</ArticleId>
            <ArticleId IdType="pubmed">26020648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S, et al.  Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2019;18:437–447. doi: 10.1158/1535-7163.MCT-18-0584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-18-0584</ArticleId>
            <ArticleId IdType="pubmed">30401696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pieters T, van Roy F. Role of cell-cell adhesion complexes in embryonic stem cell biology. J Cell Sci. 2014;127:2603–2613. doi: 10.1242/jcs.146720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.146720</ArticleId>
            <ArticleId IdType="pubmed">24931943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010;107:21677–21682. doi: 10.1073/pnas.1016234107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1016234107</ArticleId>
            <ArticleId IdType="pmc">PMC3003109</ArticleId>
            <ArticleId IdType="pubmed">21098274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2014;229:1005–1015. doi: 10.1002/jcp.24539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.24539</ArticleId>
            <ArticleId IdType="pubmed">24374897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–590. doi: 10.1016/j.ccr.2011.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.09.009</ArticleId>
            <ArticleId IdType="pmc">PMC3487108</ArticleId>
            <ArticleId IdType="pubmed">22094253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–691. doi: 10.1016/j.cell.2016.11.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.11.037</ArticleId>
            <ArticleId IdType="pmc">PMC5308465</ArticleId>
            <ArticleId IdType="pubmed">28187288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells—mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14:155–167. doi: 10.1038/nrclinonc.2016.144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2016.144</ArticleId>
            <ArticleId IdType="pubmed">27644321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leblanc R, Peyruchaud O. Metastasis: new functional implications of platelets and megakaryocytes. Blood. 2016;128:24–31. doi: 10.1182/blood-2016-01-636399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2016-01-636399</ArticleId>
            <ArticleId IdType="pubmed">27154188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, et al.  A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015;12:685–691. doi: 10.1038/nmeth.3404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.3404</ArticleId>
            <ArticleId IdType="pmc">PMC4490017</ArticleId>
            <ArticleId IdType="pubmed">25984697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprouse ML, Welte T, Boral D, Liu HN, Yin W, Vishnoi M, et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal signaling. Int J Mol Sci. 2019;20. 10.3390/ijms20081916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6514876</ArticleId>
            <ArticleId IdType="pubmed">31003475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen MB, Hajal C, Benjamin DC, Yu C, Azizgolshani H, Hynes RO, Kamm RD. Inflamed neutrophils sequestered at entrapped tumor cells via chemotactic confinement promote tumor cell extravasation. Proc Natl Acad Sci U S A. 2018;115:7022–7027. doi: 10.1073/pnas.1715932115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1715932115</ArticleId>
            <ArticleId IdType="pmc">PMC6142213</ArticleId>
            <ArticleId IdType="pubmed">29915060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–598. doi: 10.1038/nrc.2016.73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2016.73</ArticleId>
            <ArticleId IdType="pubmed">27550820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. doi: 10.3389/fimmu.2019.01835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01835</ArticleId>
            <ArticleId IdType="pmc">PMC6688105</ArticleId>
            <ArticleId IdType="pubmed">31428105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71–88. doi: 10.1038/s41576-018-0071-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41576-018-0071-5</ArticleId>
            <ArticleId IdType="pubmed">30410101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–1209. doi: 10.1056/NEJMoa1213261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1213261</ArticleId>
            <ArticleId IdType="pubmed">23484797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7:302ra133. doi: 10.1126/scitranslmed.aab0021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aab0021</ArticleId>
            <ArticleId IdType="pubmed">26311728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med. 2017;5:46. doi: 10.21037/atm.2017.01.32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm.2017.01.32</ArticleId>
            <ArticleId IdType="pmc">PMC5326656</ArticleId>
            <ArticleId IdType="pubmed">28251125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro-Giner F, Gkountela S, Donato C, Alborelli I, Quagliata L, Ng CKY, et al. Cancer diagnosis using a liquid biopsy: challenges and expectations. Diagnostics (Basel). 2018;8. doi: 10.3390/diagnostics8020031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6023445</ArticleId>
            <ArticleId IdType="pubmed">29747380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–548. doi: 10.1038/nrclinonc.2017.14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.14</ArticleId>
            <ArticleId IdType="pubmed">28252003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, et al.  Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;9:1691. doi: 10.1038/s41467-018-04001-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-04001-5</ArticleId>
            <ArticleId IdType="pmc">PMC5923255</ArticleId>
            <ArticleId IdType="pubmed">29703982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, et al.  Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016;8:363ra147. doi: 10.1126/scitranslmed.aac7037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aac7037</ArticleId>
            <ArticleId IdType="pmc">PMC5426804</ArticleId>
            <ArticleId IdType="pubmed">27807282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, et al.  In situ detection and quantification of AR-V7, AR-FL, PSA, and KRAS point mutations in circulating tumor cells. Clin Chem. 2018;64:536–546. doi: 10.1373/clinchem.2017.281295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2017.281295</ArticleId>
            <ArticleId IdType="pubmed">29301749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–1038. doi: 10.1056/NEJMoa1315815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1315815</ArticleId>
            <ArticleId IdType="pmc">PMC4201502</ArticleId>
            <ArticleId IdType="pubmed">25184630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al.  Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1:582–591. doi: 10.1001/jamaoncol.2015.1341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2015.1341</ArticleId>
            <ArticleId IdType="pmc">PMC4537351</ArticleId>
            <ArticleId IdType="pubmed">26181238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al.  Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441–1449. doi: 10.1001/jamaoncol.2016.1828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.1828</ArticleId>
            <ArticleId IdType="pmc">PMC5206761</ArticleId>
            <ArticleId IdType="pubmed">27262168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al.  Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35:2149–2156. doi: 10.1200/JCO.2016.70.1961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.70.1961</ArticleId>
            <ArticleId IdType="pmc">PMC5493048</ArticleId>
            <ArticleId IdType="pubmed">28384066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Prostate. 2018;78:576–582. doi: 10.1002/pros.23501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pros.23501</ArticleId>
            <ArticleId IdType="pubmed">29508425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, et al.  Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol. 2018;4:1179–1186. doi: 10.1001/jamaoncol.2018.1621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.1621</ArticleId>
            <ArticleId IdType="pmc">PMC6139066</ArticleId>
            <ArticleId IdType="pubmed">29955787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, et al.  Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol. 2017;71:874–882. doi: 10.1016/j.eururo.2016.11.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2016.11.024</ArticleId>
            <ArticleId IdType="pmc">PMC5401782</ArticleId>
            <ArticleId IdType="pubmed">27979426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, et al.  Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer. Eur Urol. 2019;76:676–685. doi: 10.1016/j.eururo.2019.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2019.04.006</ArticleId>
            <ArticleId IdType="pubmed">31036442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, et al.  Expression of AR-V7 and ARv (567es) in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY. Clin Cancer Res. 2019;25:1880–1888. doi: 10.1158/1078-0432.CCR-18-0320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-0320</ArticleId>
            <ArticleId IdType="pmc">PMC6432911</ArticleId>
            <ArticleId IdType="pubmed">30301829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, et al.  Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019;25:1534–1539. doi: 10.1038/s41591-019-0593-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0593-1</ArticleId>
            <ArticleId IdType="pmc">PMC6986897</ArticleId>
            <ArticleId IdType="pubmed">31591595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, et al.  A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discov. 2018;8:1286–1299. doi: 10.1158/2159-8290.CD-18-0432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-18-0432</ArticleId>
            <ArticleId IdType="pmc">PMC6170694</ArticleId>
            <ArticleId IdType="pubmed">30104333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, et al.  An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discov. 2018;8:288–303. doi: 10.1158/2159-8290.CD-16-1406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-16-1406</ArticleId>
            <ArticleId IdType="pmc">PMC6342192</ArticleId>
            <ArticleId IdType="pubmed">29301747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, et al.  Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018;115:2467–2472. doi: 10.1073/pnas.1719264115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1719264115</ArticleId>
            <ArticleId IdType="pmc">PMC5877960</ArticleId>
            <ArticleId IdType="pubmed">29453278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amantini C, Morelli MB, Nabissi M, Piva F, Marinelli O, Maggi F, et al.  Expression profiling of circulating tumor cells in pancreatic ductal adenocarcinoma patients: biomarkers predicting overall survival. Front Oncol. 2019;9:874. doi: 10.3389/fonc.2019.00874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.00874</ArticleId>
            <ArticleId IdType="pmc">PMC6746928</ArticleId>
            <ArticleId IdType="pubmed">31552188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulasinghe A, Kapeleris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery JP, et al.  The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. Cancer Med. 2018;7:5910–5919. doi: 10.1002/cam4.1832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1832</ArticleId>
            <ArticleId IdType="pmc">PMC6308060</ArticleId>
            <ArticleId IdType="pubmed">30565869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, et al.  PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–112. doi: 10.1016/j.lungcan.2018.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2018.04.001</ArticleId>
            <ArticleId IdType="pubmed">29748004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, et al.  Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 2018;7:e1438111. doi: 10.1080/2162402X.2018.1438111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1438111</ArticleId>
            <ArticleId IdType="pmc">PMC5993493</ArticleId>
            <ArticleId IdType="pubmed">29900038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosseini H, Obradović MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, et al.  Early dissemination seeds metastasis in breast cancer. Nature. 2016;540:552–558. doi: 10.1038/nature20785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature20785</ArticleId>
            <ArticleId IdType="pmc">PMC5390864</ArticleId>
            <ArticleId IdType="pubmed">27974799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, et al.  Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun. 2017;8:14944. doi: 10.1038/ncomms14944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14944</ArticleId>
            <ArticleId IdType="pmc">PMC5474888</ArticleId>
            <ArticleId IdType="pubmed">28429735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, et al.  Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016;48:758–767. doi: 10.1038/ng.3573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3573</ArticleId>
            <ArticleId IdType="pubmed">27182968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiter JG, Makohon-Moore AP, Gerold JM, Bozic I, Chatterjee K, Iacobuzio-Donahue CA, et al.  Reconstructing metastatic seeding patterns of human cancers. Nat Commun. 2017;8:14114. doi: 10.1038/ncomms14114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14114</ArticleId>
            <ArticleId IdType="pmc">PMC5290319</ArticleId>
            <ArticleId IdType="pubmed">28139641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison GJ, Cunha AT, Jojo N, Xu Y, Xu Y, Kwok E, et al. Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. Int J Cancer. 2020. 10.1002/ijc.32915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7451020</ArticleId>
            <ArticleId IdType="pubmed">32037533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr. 2014;2014:187–197. doi: 10.1093/jncimonographs/lgu014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jncimonographs/lgu014</ArticleId>
            <ArticleId IdType="pmc">PMC4841163</ArticleId>
            <ArticleId IdType="pubmed">25417232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aravanis AM, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. Cell. 2017;168:571–574. doi: 10.1016/j.cell.2017.01.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.01.030</ArticleId>
            <ArticleId IdType="pubmed">28187279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al.  Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. doi: 10.1126/scitranslmed.3007094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3007094</ArticleId>
            <ArticleId IdType="pmc">PMC4017867</ArticleId>
            <ArticleId IdType="pubmed">24553385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al.  Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–451. doi: 10.1038/nature22364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22364</ArticleId>
            <ArticleId IdType="pmc">PMC5812436</ArticleId>
            <ArticleId IdType="pubmed">28445469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, et al.  Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017;114:10202–10207. doi: 10.1073/pnas.1704961114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1704961114</ArticleId>
            <ArticleId IdType="pmc">PMC5617273</ArticleId>
            <ArticleId IdType="pubmed">28874546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar3247</ArticleId>
            <ArticleId IdType="pmc">PMC6080308</ArticleId>
            <ArticleId IdType="pubmed">29348365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9. 10.1126/scitranslmed.aan2415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6714979</ArticleId>
            <ArticleId IdType="pubmed">28814544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree IA, Uttley L, Buckley Woods H, Kikuchi H, Reiman A, Harnan S, et al.  The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. BMC Cancer. 2017;17:697. doi: 10.1186/s12885-017-3693-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-017-3693-7</ArticleId>
            <ArticleId IdType="pmc">PMC5654013</ArticleId>
            <ArticleId IdType="pubmed">29061138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, et al.  “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9:e111597. doi: 10.1371/journal.pone.0111597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0111597</ArticleId>
            <ArticleId IdType="pmc">PMC4216113</ArticleId>
            <ArticleId IdType="pubmed">25360587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16:166. doi: 10.1186/s12916-018-1157-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-018-1157-9</ArticleId>
            <ArticleId IdType="pmc">PMC6167864</ArticleId>
            <ArticleId IdType="pubmed">30285732</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
